Neuro2Go offers a convenient way to talk to a board-certified neurologist, which will now provide the Sampled Alzheimer’s Risk Test, to assess the genetic risk of cognitive decline due to Alzheimer’s disease. The test uses Cytox’s genoSCORE technology to generate a comprehensive genetic analysis for the risk of Alzheimer’s disease from a simple saliva sample. …
Jeffrey Gelblum, MD, a board-certified neurologist with First Choice Neurology and Neuro2Go, the nation’s largest neurology practice, treated the first patient in Florida with Biogen’s Aduhelm (aducanumab), an infusion treatment for early-stage Alzheimer’s patients. Aduhelm decreases amyloid plaque in the brain, which is a marker for Alzheimer’s disease. Florida’s first Aduhelm patient is a middle-aged …
The First Florida Patient to Receive Biogen’s Aduhelm for Alzheimer’s Disease Read More »
If you or a loved one is suffering from memory loss, a new FDA-approved treatment may be just around the corner for Alzheimer’s disease. Could an amyloid-targeting therapy finally be poised for approval? For more than a quarter-century, researchers have targeted amyloid, a protein that clogs the brains of many Alzheimer’s patients. It was first …